ROR1 in MEC1-ROR1 cells associates with DOCK2. (A) Immunoblot analysis of anti-ROR1 (cirmtuzumab) immunoprecipitation (ip) or Ctrl-IgG ip, as indicated at the top, using lysates prepared from MEC1-ROR1 cells; the membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. (B) Immunoblot analysis of anti-DOCK2 ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from MEC1-ROR1 cells; membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. (C) Immunoblot analysis of anti-DOCK2 ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from ROR1-negative cell line, MEC1; the membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. (D) Immunoblot analysis of anti-ROR1 (cirmtuzumab) ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from MEC1-ROR1 cells that had been treated with Wnt5a neutralizing antibody (2 μg/mL; R & D) for the times indicated at the bottom (in hours); membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. An immunoblot of the whole-cell lysates of the MEC1-ROR1 cells treated with Wnt5a neutralizing antibody and probed with anti-DOCK2 mAb is provided in the bottom panel. (E) Immunoblot analysis of anti-ROR1 (4A5) ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from MEC1-ROR1 cells that had been treated with cirmtuzumab (10 μg/ml) for the times indicated at the bottom (in hours); membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. An immunoblot of the whole-cell lysates of the CLL treated with cirmtuzumab and probed with anti-DOCK2 mAb is provided in the bottom panel.